الرئيسية » أرشيف الوسم : Featured (صفحة 6)

أرشيف الوسم : Featured

The Emirates Thalassaemia Society launches the 12th edition of the ”What is Thalassaemia?”competition

  The Emirates Thalassemia Society (ETS), a prominent TIF’s Member, in collaboration with the United Arab Emirates’ Ministry of Education, is organising the 12th Season of  the ”What is Thalassemia?” Competition. The competition has been running successfully in all the schools, universities and colleges across UAE since 2007. It has ...

أكمل القراءة »

Global Blood Therapeutics & Syros Pharma team up on novel therapies for β-thalassaemia & SCD

Global Blood Therapeutics (GBT) and Syros Pharma announced yesterday their partnership to discover, develop and commercialize novel therapies for SickleCell Disease (SCD) and β-thalassaemia.  Under the agreement, Syros will use its leading gene control platform to identify therapeutic targets and discover drugs that induce fetal hemoglobin, and GBT will receive ...

أكمل القراءة »

TIF by the side of thalassaemia patients in Syria

  The World Health Organisation (WHO) has contacted the Thalassaemia International Federation (TIF) to request the provision of its expertise and technical support on the thalassaemia care and management of patients in the North West Syria region. Currently, this region includes four Thalassaemia Centres with approximately 500 patients. These patients ...

أكمل القراءة »

New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019

  Celgene Corporation, Acceleron Pharma, Sangamo Therapeutics & Agios Pharmaceuticals are expected to present new and updated data on the progress of key ongoing therapies for thalassaemia and sickle cell disease (SCD) in the 61st American Society of Hematology Annual Meeting to take place in Orlando, Florida, 7-10 December 2019. ...

أكمل القراءة »

Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA

  The European Medicines Agency’s (EMA) has recently granted marketing authorisation for the medicinal product ”Deferasirox Mylan”, intended for the treatment of chronic iron overload due to blood transfusions in patients with β-thalassaemia major, non-transfusion-dependent thalassaemia syndromes and other anaemias. The manufacturer of this medicinal product is Mylan S.A.S. ”Deferasirox Mylan” will be ...

أكمل القراءة »

US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV

  The National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation will each invest $100 million over the next four years to speed the development of affordable gene therapies for sickle cell disease (SCD) and the human immunodeficiency virus (HIV) on a global scale. The collaboration between the NIH and the Gates Foundation sets ...

أكمل القراءة »

High-Level Thalassaemia & Sickle Cell Disease Healthcare Professionals Summit – 1 & 2 November 2019

After the successful Capacity Building Workshop for Patient Organizations & Patients with thalassaemia in Hamburg, Germany, TIF will be traveling to Thessaloniki, Greece for a High-Level Thalassaemia & Sickle Cell Disease Healthcare Professionals’ Summit, to be held on 1-2 November 2019. Seeking to inform the healthcare community working in Europe ...

أكمل القراءة »